CRM1在胰腺癌中的预后价值。

Prognostic value of CRM1 in pancreas cancer.

作者信息

Huang Wei-yi, Yue Lu, Qiu Wen-shen, Wang Li-Wei, Zhou Xiao-han, Sun Yuan-jue

机构信息

Department of Oncology, Affiliated People's 1st Hospital, Shanghai Jiaotong University, Shanghai, PR China 200085.

出版信息

Clin Invest Med. 2009 Dec 1;32(6):E315.

PMID:20003838

Abstract

PURPOSE

Pancreatic cancer is a highly aggressive malignant tumour with poor prognosis. The median survival is only 6 months. This study investigated the prognostic value of nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 (CRM1) expression in pancreas cancer.

METHODS

CRM1 expression was detected, by Western blot, in pancreatic tissue from 69 cancer patients and 10 normal subjects.

RESULTS

CRM1 showed increased expression in pancreatic cancer tissue (P = 0.007). The high expression of CRM1 was associated with increased serum levels of CEA (P = 0.002) and CA19-9 (P = 0.005). There was an association between CRM1 expression and tumour size (P = 0.01), lymphadenopathy (P = 0.004) and liver metastasis (P = 0.003). High CRM1 expression was not correlated with the other clinicopathological parameters. High CRM1 expression was a prognostic indicator for progression-free survival (PFS) (P = 0.006) as well as overall survival (OS) (P = 0.001). Expression of CRM1 was an independent prognostic parameter for poorer PFS and OS (95% CI, 1.27-5.39).

CONCLUSIONS

CRM1 expression demonstrated prognostic value in pancreatic cancer. Prospective studies are required to determine the prognostic role of high expression of CRM1 in pancreatic cancer.

摘要

目的

胰腺癌是一种侵袭性很强的恶性肿瘤，预后较差。中位生存期仅6个月。本研究调查了核输出蛋白染色体区域维持蛋白/输出蛋白1/Xpo1（CRM1）在胰腺癌中的预后价值。

方法

采用蛋白质免疫印迹法检测69例癌症患者和10例正常受试者胰腺组织中的CRM1表达。

结果

CRM1在胰腺癌组织中表达增加（P = 0.007）。CRM1高表达与血清癌胚抗原（CEA）水平升高（P = 0.002）和糖类抗原19-9（CA19-9）水平升高（P = 0.005）相关。CRM1表达与肿瘤大小（P = 0.01）、淋巴结病（P = 0.004）和肝转移（P = 0.003）之间存在关联。CRM1高表达与其他临床病理参数无关。CRM1高表达是无进展生存期（PFS）（P = 0.006）以及总生存期（OS）（P = 0.001）的预后指标。CRM1表达是PFS和OS较差的独立预后参数（95%可信区间，1.27 - 5.39）。